The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Medivation

  • MDVN
  • NASDAQ
  • Consumer Products
  • Latest 105.70
  • Currency US$
  • Change 2.96
  • Percent Change 2.881 %
  • Volume 1,577,456
  • Fri Oct 31, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 104.37
  • Previous Close 102.74
  • High 108.835
  • Low 103.21
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High10/31 108.835
  • 52-week Low04/14 54.37
  • Beta 5.645
  • Market Cap 8,068.08M
  • EPS 0.27
  • P/E 391.481
  • Forward P/E 30.73
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $313,980,000
  • Earnings $-29,100,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $241,460,000
  • Current Ratio 3.87

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $398,060,000
  • Liabilities $316,100,000
  • Liabilities-to-Equity Ratio 3.86

Price Ratios

  • Price to Sales 25.70
  • Price to Book 98.42
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Aug 7 $0.28 Nov 6 $1.05
Surprises Aug 7 114.29% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Nov 01, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices

Related Securities
Symbol Type Latest % Chg

Officers

  • David T. Hung, M.D. President; C.E.O. & Director
  • C. Patrick Machado Chief Business Officer & C.F.O
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

525 MARKET STREET 36TH FLOOR
SAN FRANCISCO, CA
94105

Phone: (415)-543-3470
Fax: (415)-5433411

investors@medivation.com
www.medivation.com

Ideas & Discussion

Live Discussion of MDVN on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.